What is HC Wainwright's Forecast for KALV FY2029 Earnings?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Equities research analysts at HC Wainwright reduced their FY2029 earnings per share (EPS) estimates for shares of KalVista Pharmaceuticals in a report issued on Friday, December 6th. HC Wainwright analyst A. Fein now anticipates that the specialty pharmaceutical company will post earnings of $1.24 per share for the year, down from their previous estimate of $1.36. HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($2.70) per share.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.91) by $0.04.

Several other analysts have also weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating on shares of KalVista Pharmaceuticals in a report on Monday. Needham & Company LLC reiterated a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Thursday.

KalVista Pharmaceuticals Trading Down 4.8 %

KALV stock traded down $0.47 during trading on Monday, reaching $9.34. 318,003 shares of the stock were exchanged, compared to its average volume of 478,207. KalVista Pharmaceuticals has a twelve month low of $7.39 and a twelve month high of $16.88. The company has a market capitalization of $461.58 million, a P/E ratio of -2.57 and a beta of 0.85. The stock has a 50 day simple moving average of $10.85 and a 200-day simple moving average of $11.81.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 7,627 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $9.75, for a total transaction of $74,363.25. Following the sale, the chief executive officer now owns 274,596 shares in the company, valued at approximately $2,677,311. This represents a 2.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the transaction, the insider now directly owns 94,199 shares of the company's stock, valued at $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,291 shares of company stock worth $304,086 over the last quarter. Company insiders own 10.50% of the company's stock.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of KalVista Pharmaceuticals by 4.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company's stock valued at $263,000 after purchasing an additional 944 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in KalVista Pharmaceuticals by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 135,600 shares of the specialty pharmaceutical company's stock valued at $1,597,000 after purchasing an additional 23,547 shares during the last quarter. nVerses Capital LLC acquired a new position in KalVista Pharmaceuticals in the second quarter valued at about $25,000. Rhumbline Advisers boosted its holdings in KalVista Pharmaceuticals by 12.5% during the second quarter. Rhumbline Advisers now owns 53,228 shares of the specialty pharmaceutical company's stock worth $627,000 after buying an additional 5,908 shares during the last quarter. Finally, ClariVest Asset Management LLC grew its position in shares of KalVista Pharmaceuticals by 2.8% during the 2nd quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company's stock worth $673,000 after buying an additional 1,535 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).